Gain Therapeutics, Inc. (GANX)
Nasdaq: GANX · Pharmaceutical Preparations · Bethesda, MD · filing with the SEC since 2020
Who runs Gain Therapeutics, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Mack Gene
CEO, President. First filing Apr 2024, latest Mar 26, 2026, 1 filing in all.
Officers reporting now
4
of 9 people with a filing in the last fifteen months
Directors reporting now
5
14 people on the record since 2021
Officerssales are open-market, Oct 30, 2025 to Oct 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Weidner Jeanette | See Remarks | Oct 2026 | Oct 30, 2026 | none |
| Islam Khalid | Executive Chairman | Mar 2021 | Jul 17, 2026 | none |
| Mack Gene | CEO, President | Apr 2024 | Mar 26, 2026 | none |
| Fuggetta Gianluca | Principal Accounting and Financial Officer | Dec 2022 | Mar 26, 2026 | none |
Directorssales are open-market, Oct 30, 2025 to Oct 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Goldstein Dov A Md | director | Mar 2021 | Jul 17, 2026 | none |
| Hasler Hans Peter | director | Mar 2021 | Jul 17, 2026 | none |
| Melincoff Gwen A | director | Mar 2021 | Jul 17, 2026 | none |
| Nicaise Claude | director | Mar 2021 | Jul 17, 2026 | none |
| Riley Jeffrey Scott | director | Mar 2021 | Jul 17, 2026 | none |
Earlier names on the record5, newest filing first
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.